首页 > 最新文献

Clinical and Experimental Nephrology最新文献

英文 中文
Association of hyperphosphatemia with renal prognosis in patients with autosomal dominant polycystic kidney disease. 常染色体显性多囊肾患者的高磷血症与肾脏预后的关系。
IF 2.2 4区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-09-25 DOI: 10.1007/s10157-024-02568-6
Kosaku Nitta, Hiroshi Kataoka, Shun Manabe, Shiho Makabe, Taro Akihisa, Yusuke Ushio, Momoko Seki, Ken Tsuchiya, Junichi Hoshino, Toshio Mochizuki

Background: Serum phosphate (P) levels are generally lower in autosomal dominant polycystic kidney disease (ADPKD) than in other kidney disorders, potentially masking the clinical significance of hyperphosphatemia. This study aimed to determine if serum P levels can predict renal outcomes in ADPKD patients.

Methods: We included 235 patients with ADPKD who were not taking drugs to treat hyperphosphatemia. Survival analysis was performed for the renal outcome of a 50% reduction in estimated glomerular filtration rate or initiation of renal replacement therapy.

Results: Multivariable Cox regression analyses revealed that serum P (1 mg/dL increase, HR = 2.03, P < 0.0001) was a significant risk factor for kidney disease progression. Similarly, hyperphosphatemia (P > 3.5 mg/dL, HR = 2.05; P > 4.0 mg/dL, HR = 1.90; P > 4.5 mg/dL, HR = 2.78; P > 5.0 mg/dL, HR = 27.22) was significantly associated with renal prognosis. Kaplan-Meier analysis showed significantly lower kidney survival rates in patients with P > 3.5 mg/dL than in those without hyperphosphatemia (log-rank test, P < 0.0001), and similar Kaplan-Meier analysis results were found for P > 4.0 mg/dL, P > 4.5 mg/dL, and P > 5.0 mg/dL. The 2 year kidney survival rate for ADPKD patients with P > 3.5 mg/dL was 66.7% overall and 41.4% in those with stage 4-5 CKD. For patients with P > 4.0 mg/dL, the survival rate dropped to 46.8% overall and 28.2% in those with stage 4-5 CKD, indicating a very poor prognosis.

Conclusion: Hyperphosphatemia was associated with renal prognosis in patients with ADPKD. In these patients, attention should be paid to even mild serum P elevation of > 3.5 or > 4.0 mg/dL.

背景:常染色体显性多囊肾(ADPKD)患者的血清磷酸盐(P)水平通常低于其他肾脏疾病,这可能会掩盖高磷血症的临床意义。本研究旨在确定血清 P 水平能否预测 ADPKD 患者的肾脏预后:我们纳入了 235 名未服用治疗高磷血症药物的 ADPKD 患者。对估计肾小球滤过率降低 50%或开始肾脏替代治疗的肾脏结局进行了生存分析:多变量 Cox 回归分析显示,血清 P(增加 1 毫克/分升,HR = 2.03;P 3.5 毫克/分升,HR = 2.05;P > 4.0 毫克/分升,HR = 1.90;P > 4.5 毫克/分升,HR = 2.78;P > 5.0 毫克/分升,HR = 27.22)与肾脏预后显著相关。Kaplan-Meier 分析显示,P > 3.5 mg/dL 患者的肾脏存活率明显低于无高磷血症患者(对数秩检验,P 4.0 mg/dL、P > 4.5 mg/dL 和 P > 5.0 mg/dL)。P>3.5毫克/分升的ADPKD患者2年肾脏存活率总体为66.7%,4-5期CKD患者为41.4%。P>4.0毫克/分升的患者的总体存活率降至46.8%,4-5期慢性肾脏病患者的存活率降至28.2%,预后极差:结论:高磷血症与ADPKD患者的肾脏预后有关。结论:高磷血症与 ADPKD 患者的肾脏预后有关。对于这些患者,即使血清 P 轻度升高(> 3.5 或 > 4.0 mg/dL)也应引起注意。
{"title":"Association of hyperphosphatemia with renal prognosis in patients with autosomal dominant polycystic kidney disease.","authors":"Kosaku Nitta, Hiroshi Kataoka, Shun Manabe, Shiho Makabe, Taro Akihisa, Yusuke Ushio, Momoko Seki, Ken Tsuchiya, Junichi Hoshino, Toshio Mochizuki","doi":"10.1007/s10157-024-02568-6","DOIUrl":"https://doi.org/10.1007/s10157-024-02568-6","url":null,"abstract":"<p><strong>Background: </strong>Serum phosphate (P) levels are generally lower in autosomal dominant polycystic kidney disease (ADPKD) than in other kidney disorders, potentially masking the clinical significance of hyperphosphatemia. This study aimed to determine if serum P levels can predict renal outcomes in ADPKD patients.</p><p><strong>Methods: </strong>We included 235 patients with ADPKD who were not taking drugs to treat hyperphosphatemia. Survival analysis was performed for the renal outcome of a 50% reduction in estimated glomerular filtration rate or initiation of renal replacement therapy.</p><p><strong>Results: </strong>Multivariable Cox regression analyses revealed that serum P (1 mg/dL increase, HR = 2.03, P < 0.0001) was a significant risk factor for kidney disease progression. Similarly, hyperphosphatemia (P > 3.5 mg/dL, HR = 2.05; P > 4.0 mg/dL, HR = 1.90; P > 4.5 mg/dL, HR = 2.78; P > 5.0 mg/dL, HR = 27.22) was significantly associated with renal prognosis. Kaplan-Meier analysis showed significantly lower kidney survival rates in patients with P > 3.5 mg/dL than in those without hyperphosphatemia (log-rank test, P < 0.0001), and similar Kaplan-Meier analysis results were found for P > 4.0 mg/dL, P > 4.5 mg/dL, and P > 5.0 mg/dL. The 2 year kidney survival rate for ADPKD patients with P > 3.5 mg/dL was 66.7% overall and 41.4% in those with stage 4-5 CKD. For patients with P > 4.0 mg/dL, the survival rate dropped to 46.8% overall and 28.2% in those with stage 4-5 CKD, indicating a very poor prognosis.</p><p><strong>Conclusion: </strong>Hyperphosphatemia was associated with renal prognosis in patients with ADPKD. In these patients, attention should be paid to even mild serum P elevation of > 3.5 or > 4.0 mg/dL.</p>","PeriodicalId":10349,"journal":{"name":"Clinical and Experimental Nephrology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inhibition of ADAM17 attenuates high glucose-induced angiogenesis and inflammation in endothelial cells partly through down-regulation of GRO-α/CXCR2 expression: implications in peritoneal dialysis. 抑制 ADAM17 可部分通过下调 GRO-α/CXCR2 的表达减轻高血糖诱导的内皮细胞血管生成和炎症:对腹膜透析的影响。
IF 2.2 4区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-09-21 DOI: 10.1007/s10157-024-02546-y
Na Jiang, Hao Feng, Weizhen Xie, Leyi Gu, Wei Fang, Tingting Ding, Jiangzi Yuan

Background: Angiogenesis and inflammation are key events leading to peritoneal morphologic alteration and ultrafiltration failure in patients undergoing peritoneal dialysis (PD). The current study aims to explore the role of ADAM17 in the angiogenetic and inflammatory responses of endothelial cells.

Methods: Human umbilical vein endothelial cells (HUVECs) were cultured and treated with a high glucose-containing medium. In parallel experiments, the expression of ADAM17 in HUVECs was inhibited by SiRNA interference. The mRNA and protein expression of ADAM17, GRO-α and CXCR2 were assessed by qPCR and Western blotting, respectively. The concentrations of GRO-α, VEGF, IL-6 and TNF-α in the cellular supernatants were determined by ELISA. Tube formation and migration of HUVECs were evaluated by Matrigel and transwell migration apparatus.

Results: High glucose increased the expression of ADAM17, CXCR2 and GRO-α in cultured HUVECs. RNA silencing of ADAM17 abolished high glucose-mediated increase of GRO-α and CXCR2, which were accompanied by reduced secretion of VEGF, IL-6, TNF-α, as well as tube formation and cell migration in HUVECs.

Conclusions: Inhibition of ADAM17 ameliorates high glucose-induced angiogenic and inflammatory responses in endothelial cells partly through down-regulation of GRO-α/CXCR2 expression.

背景:血管生成和炎症是导致腹膜透析(PD)患者腹膜形态改变和超滤失败的关键事件。本研究旨在探讨 ADAM17 在内皮细胞血管生成和炎症反应中的作用。在平行实验中,通过 SiRNA 干扰抑制 ADAM17 在 HUVECs 中的表达。分别通过 qPCR 和 Western 印迹法评估 ADAM17、GRO-α 和 CXCR2 的 mRNA 和蛋白表达。细胞上清液中 GRO-α、VEGF、IL-6 和 TNF-α 的浓度通过酶联免疫吸附测定。用 Matrigel 和 transwell 迁移仪评估 HUVECs 的管形成和迁移情况:结果:高糖增加了培养的 HUVECs 中 ADAM17、CXCR2 和 GRO-α 的表达。ADAM17的RNA沉默可抑制高糖介导的GRO-α和CXCR2的增加,同时降低血管内皮生长因子、IL-6、TNF-α的分泌,并减少HUVECs中管的形成和细胞迁移:结论:抑制ADAM17可部分通过下调GRO-α/CXCR2的表达改善高血糖诱导的内皮细胞血管生成和炎症反应。
{"title":"Inhibition of ADAM17 attenuates high glucose-induced angiogenesis and inflammation in endothelial cells partly through down-regulation of GRO-α/CXCR2 expression: implications in peritoneal dialysis.","authors":"Na Jiang, Hao Feng, Weizhen Xie, Leyi Gu, Wei Fang, Tingting Ding, Jiangzi Yuan","doi":"10.1007/s10157-024-02546-y","DOIUrl":"https://doi.org/10.1007/s10157-024-02546-y","url":null,"abstract":"<p><strong>Background: </strong>Angiogenesis and inflammation are key events leading to peritoneal morphologic alteration and ultrafiltration failure in patients undergoing peritoneal dialysis (PD). The current study aims to explore the role of ADAM17 in the angiogenetic and inflammatory responses of endothelial cells.</p><p><strong>Methods: </strong>Human umbilical vein endothelial cells (HUVECs) were cultured and treated with a high glucose-containing medium. In parallel experiments, the expression of ADAM17 in HUVECs was inhibited by SiRNA interference. The mRNA and protein expression of ADAM17, GRO-α and CXCR2 were assessed by qPCR and Western blotting, respectively. The concentrations of GRO-α, VEGF, IL-6 and TNF-α in the cellular supernatants were determined by ELISA. Tube formation and migration of HUVECs were evaluated by Matrigel and transwell migration apparatus.</p><p><strong>Results: </strong>High glucose increased the expression of ADAM17, CXCR2 and GRO-α in cultured HUVECs. RNA silencing of ADAM17 abolished high glucose-mediated increase of GRO-α and CXCR2, which were accompanied by reduced secretion of VEGF, IL-6, TNF-α, as well as tube formation and cell migration in HUVECs.</p><p><strong>Conclusions: </strong>Inhibition of ADAM17 ameliorates high glucose-induced angiogenic and inflammatory responses in endothelial cells partly through down-regulation of GRO-α/CXCR2 expression.</p>","PeriodicalId":10349,"journal":{"name":"Clinical and Experimental Nephrology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimal course of pre-emptive rituximab administration for long-term disease remission in patients with complicated steroid-dependent nephrotic syndrome requiring immunosuppressive agents after rituximab. 在使用利妥昔单抗后需要使用免疫抑制剂的复杂类固醇依赖性肾病综合征患者中,使用利妥昔单抗抢先治疗以实现长期疾病缓解的最佳疗程。
IF 2.2 4区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-09-01 Epub Date: 2024-03-08 DOI: 10.1007/s10157-024-02484-9
Yusuke Gonda, Shuichiro Fujinaga
{"title":"Optimal course of pre-emptive rituximab administration for long-term disease remission in patients with complicated steroid-dependent nephrotic syndrome requiring immunosuppressive agents after rituximab.","authors":"Yusuke Gonda, Shuichiro Fujinaga","doi":"10.1007/s10157-024-02484-9","DOIUrl":"10.1007/s10157-024-02484-9","url":null,"abstract":"","PeriodicalId":10349,"journal":{"name":"Clinical and Experimental Nephrology","volume":" ","pages":"953-954"},"PeriodicalIF":2.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140058827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Guidelines for clinical evaluation of chronic kidney disease in early stages : AMED research on regulatory science of pharmaceuticals and medical devices. 慢性肾脏病早期临床评估指南 :AMED关于药品和医疗器械监管科学的研究。
IF 2.2 4区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-09-01 Epub Date: 2024-07-06 DOI: 10.1007/s10157-024-02514-6
Yuka Sugawara, Eiichiro Kanda, Takayuki Hamano, Seiji Itano, Hirokazu Okada, Koji Tomori, Yusuke Watanabe, Wataru Asakura, Yoshitaka Isaka, Kunitoshi Iseki, Tomoko Usui, Yusuke Suzuki, Mototsugu Tanaka, Rimei Nishimura, Kei Fukami, Kunihiro Matsushita, Jun Wada, Hirotaka Watada, Kohjiro Ueki, Naoki Kashihara, Masaomi Nangaku

Background: For the development of pharmaceutical products in kidney field, appropriate surrogate endpoints which can predict long-term prognosis are needed as an alternative to hard endpoints, such as end-stage kidney disease. Though international workshop has proposed estimated glomerular filtration rate (GFR) slope reduction of 0.5-1.0 mL/min/1.73 m /year and 30% decrease in albuminuria/proteinuria as surrogate endpoints in early and advanced chronic kidney disease (CKD), it was not clear whether these are applicable to Japanese patients.

Methods: We analyzed J-CKD-DB and CKD-JAC, Japanese databases/cohorts of CKD patients, and J-DREAMS, a Japanese database of patients with diabetes mellitus to investigate the applicability of eGFR slope and albuminuria/proteinuria to the Japanese population. Systematic review on those endpoints was also conducted including the results of clinical trials published after the above proposal.

Results: Our analysis showed an association between eGFR slope and the risk of end-stage kidney disease. A 30% decrease in albuminuria/proteinuria over 2 years corresponded to a 20% decrease in the risk of end-stage kidney disease patients with baseline UACR ≥ 30 mg/gCre or UPCR ≥ 0.15 g/gCre in the analysis of CKD-JAC, though this analysis was not performed on the other database/cohort. Those results suggested similar trends to those of the systematic review.

Conclusion: The results suggested that eGFR slope and decreased albuminuria/proteinuria may be used as a surrogate endpoint in clinical trials for early CKD (including diabetic kidney disease) in Japanese population, though its validity and cutoff values must be carefully considered based on the latest evidence and other factors.

背景:为了开发肾脏领域的药物产品,需要有能够预测长期预后的适当替代终点来替代硬终点,如终末期肾病。虽然国际研讨会已提出将肾小球滤过率(GFR)估计斜率降低 0.5-1.0 mL/min/1.73 m /year 和白蛋白尿/蛋白尿降低 30% 作为早期和晚期慢性肾病(CKD)的替代终点,但尚不清楚这些终点是否适用于日本患者:我们分析了日本 CKD 患者数据库/队列 J-CKD-DB 和 CKD-JAC,以及日本糖尿病患者数据库 J-DREAMS,以研究 eGFR 斜率和白蛋白尿/蛋白尿是否适用于日本人群。我们还对这些终点进行了系统回顾,包括在上述提议之后发表的临床试验结果:结果:我们的分析表明,eGFR斜率与终末期肾病风险之间存在关联。在 CKD-JAC 的分析中,白蛋白尿/蛋白尿在 2 年内降低 30% 相当于基线 UACR ≥ 30 mg/gCre 或 UPCR ≥ 0.15 g/gCre 的终末期肾病患者风险降低 20%,但这一分析未在其他数据库/队列中进行。这些结果与系统综述的趋势相似:结果表明,eGFR 斜率和白蛋白尿/蛋白尿减少可作为日本人群早期 CKD(包括糖尿病肾病)临床试验的替代终点,但其有效性和临界值必须根据最新证据和其他因素仔细考虑。
{"title":"Guidelines for clinical evaluation of chronic kidney disease in early stages : AMED research on regulatory science of pharmaceuticals and medical devices.","authors":"Yuka Sugawara, Eiichiro Kanda, Takayuki Hamano, Seiji Itano, Hirokazu Okada, Koji Tomori, Yusuke Watanabe, Wataru Asakura, Yoshitaka Isaka, Kunitoshi Iseki, Tomoko Usui, Yusuke Suzuki, Mototsugu Tanaka, Rimei Nishimura, Kei Fukami, Kunihiro Matsushita, Jun Wada, Hirotaka Watada, Kohjiro Ueki, Naoki Kashihara, Masaomi Nangaku","doi":"10.1007/s10157-024-02514-6","DOIUrl":"10.1007/s10157-024-02514-6","url":null,"abstract":"<p><strong>Background: </strong>For the development of pharmaceutical products in kidney field, appropriate surrogate endpoints which can predict long-term prognosis are needed as an alternative to hard endpoints, such as end-stage kidney disease. Though international workshop has proposed estimated glomerular filtration rate (GFR) slope reduction of 0.5-1.0 mL/min/1.73 m /year and 30% decrease in albuminuria/proteinuria as surrogate endpoints in early and advanced chronic kidney disease (CKD), it was not clear whether these are applicable to Japanese patients.</p><p><strong>Methods: </strong>We analyzed J-CKD-DB and CKD-JAC, Japanese databases/cohorts of CKD patients, and J-DREAMS, a Japanese database of patients with diabetes mellitus to investigate the applicability of eGFR slope and albuminuria/proteinuria to the Japanese population. Systematic review on those endpoints was also conducted including the results of clinical trials published after the above proposal.</p><p><strong>Results: </strong>Our analysis showed an association between eGFR slope and the risk of end-stage kidney disease. A 30% decrease in albuminuria/proteinuria over 2 years corresponded to a 20% decrease in the risk of end-stage kidney disease patients with baseline UACR ≥ 30 mg/gCre or UPCR ≥ 0.15 g/gCre in the analysis of CKD-JAC, though this analysis was not performed on the other database/cohort. Those results suggested similar trends to those of the systematic review.</p><p><strong>Conclusion: </strong>The results suggested that eGFR slope and decreased albuminuria/proteinuria may be used as a surrogate endpoint in clinical trials for early CKD (including diabetic kidney disease) in Japanese population, though its validity and cutoff values must be carefully considered based on the latest evidence and other factors.</p>","PeriodicalId":10349,"journal":{"name":"Clinical and Experimental Nephrology","volume":" ","pages":"847-865"},"PeriodicalIF":2.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11341658/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141544568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mind the gap in kidney care: translating what we know into what we do. 关注肾脏护理中的差距:将我们的知识转化为我们的行动。
IF 2.2 4区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-09-01 Epub Date: 2024-07-06 DOI: 10.1007/s10157-024-02518-2
Valerie A Luyckx, Katherine R Tuttle, Dina Abdellatif, Ricardo Correa-Rotter, Winston W S Fung, Agnès Haris, Li-Li Hsiao, Makram Khalife, Latha A Kumaraswami, Fiona Loud, Vasundhara Raghavan, Stefanos Roumeliotis, Marianella Sierra, Ifeoma Ulasi, Bill Wang, Siu-Fai Lui, Vassilios Liakopoulos, Alessandro Balducci

Historically, it takes an average of 17 years to move new treatments from clinical evidence to daily practice. Given the highly effective treatments now available to prevent or delay kidney disease onset and progression, this is far too long. The time is now to narrow the gap between what we know and what we do. Clear guidelines exist for the prevention and management of common risk factors for kidney disease, such as hypertension and diabetes, but only a fraction of people with these conditions worldwide are diagnosed, and even fewer are treated to target. Similarly, the vast majority of people living with kidney disease are unaware of their condition, because in the early stages, it is often silent. Even among patients who have been diagnosed, many do not receive appropriate treatment for kidney disease. Considering the serious consequences of kidney disease progression, kidney failure, or death, it is imperative that treatments are initiated early and appropriately. Opportunities to diagnose and treat kidney disease early must be maximized beginning at the primary care level. Many systematic barriers exist, ranging from patient to clinician to health systems to societal factors. To preserve and improve kidney health for everyone everywhere, each of these barriers must be acknowledged so that sustainable solutions are developed and implemented without further delay.

从历史上看,新疗法从临床证据转化为日常实践平均需要 17 年的时间。鉴于目前已有的高效疗法可以预防或延缓肾病的发生和发展,这个时间太长了。现在是缩小我们所知道的与我们所做的之间差距的时候了。对于高血压和糖尿病等肾脏病常见风险因素的预防和管理,已有明确的指导方针,但全世界只有一小部分肾脏病患者被确诊,接受目标治疗的患者则更少。同样,绝大多数肾病患者都不知道自己的病情,因为在早期阶段,肾病往往是无声无息的。即使在已经确诊的患者中,许多人也没有接受适当的肾病治疗。考虑到肾病恶化、肾衰竭或死亡的严重后果,必须及早开始适当的治疗。必须从初级保健开始,最大限度地利用早期诊断和治疗肾病的机会。从患者到临床医生,从医疗系统到社会因素,存在着许多系统性障碍。为了维护和改善世界各地每个人的肾脏健康,必须认识到这些障碍中的每一个,以便制定和实施可持续的解决方案,不再拖延。
{"title":"Mind the gap in kidney care: translating what we know into what we do.","authors":"Valerie A Luyckx, Katherine R Tuttle, Dina Abdellatif, Ricardo Correa-Rotter, Winston W S Fung, Agnès Haris, Li-Li Hsiao, Makram Khalife, Latha A Kumaraswami, Fiona Loud, Vasundhara Raghavan, Stefanos Roumeliotis, Marianella Sierra, Ifeoma Ulasi, Bill Wang, Siu-Fai Lui, Vassilios Liakopoulos, Alessandro Balducci","doi":"10.1007/s10157-024-02518-2","DOIUrl":"10.1007/s10157-024-02518-2","url":null,"abstract":"<p><p>Historically, it takes an average of 17 years to move new treatments from clinical evidence to daily practice. Given the highly effective treatments now available to prevent or delay kidney disease onset and progression, this is far too long. The time is now to narrow the gap between what we know and what we do. Clear guidelines exist for the prevention and management of common risk factors for kidney disease, such as hypertension and diabetes, but only a fraction of people with these conditions worldwide are diagnosed, and even fewer are treated to target. Similarly, the vast majority of people living with kidney disease are unaware of their condition, because in the early stages, it is often silent. Even among patients who have been diagnosed, many do not receive appropriate treatment for kidney disease. Considering the serious consequences of kidney disease progression, kidney failure, or death, it is imperative that treatments are initiated early and appropriately. Opportunities to diagnose and treat kidney disease early must be maximized beginning at the primary care level. Many systematic barriers exist, ranging from patient to clinician to health systems to societal factors. To preserve and improve kidney health for everyone everywhere, each of these barriers must be acknowledged so that sustainable solutions are developed and implemented without further delay.</p>","PeriodicalId":10349,"journal":{"name":"Clinical and Experimental Nephrology","volume":" ","pages":"835-846"},"PeriodicalIF":2.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11341759/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141544569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Marked vascular calcification in a patient on hemodialysis. 一名血液透析患者的血管明显钙化。
IF 2.2 4区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-08-22 DOI: 10.1007/s10157-024-02547-x
Kazuho Oe, Yohei Koyashiki, Shin-Ichi Takeda
{"title":"Marked vascular calcification in a patient on hemodialysis.","authors":"Kazuho Oe, Yohei Koyashiki, Shin-Ichi Takeda","doi":"10.1007/s10157-024-02547-x","DOIUrl":"https://doi.org/10.1007/s10157-024-02547-x","url":null,"abstract":"","PeriodicalId":10349,"journal":{"name":"Clinical and Experimental Nephrology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142016575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The phase angle before transplantation can predict the status of low muscle mass after kidney transplantation. 移植前的相位角可预测肾移植后的低肌肉质量状况。
IF 2.2 4区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-08-22 DOI: 10.1007/s10157-024-02543-1
Hyo Jin Kim, Eun Young Seong, Hyuk Jae Jung, Sang Heon Song

Background: This study aimed to evaluate the association between phase angle, muscle strength, and muscle mass in patients undergoing kidney transplantation.

Methods: Patients whose pre- and follow-up phase angles were measured after kidney transplantation were enrolled. Phase angle and body composition were measured using a multi-frequency bioimpedance analysis device before and at 7 and 14 days and 3, 6, and 12 months after transplantation. Muscle strength was evaluated using handgrip strength (HGS). Low HGS was defined as < 28 kg in males and < 18 kg in females. Low muscle mass was defined as an appendicular lean mass index of < 7.0 kg/m2 in males and < 5.7 kg/m2 in females.

Results: Eighty-eight patients (mean age 52.3 ± 10.1 years) were analyzed. The mean phase angle of pre-transplantation was 5.0 ± 1.0°. Body fat percentage was significantly higher at 6 and 12 months after transplantation than pre-transplantation (P < 0.0001). Twelve months after kidney transplantation, the prevalence of low HGS decreased (pre-transplantation vs. 12 months post-transplantation: 28.4% vs. 17.0%), and the prevalence of low muscle mass (pre-transplantation vs. 12 months post-transplantation: 21.6% vs. 28.4%) increased. The pre-transplantation phase angle was significantly associated with low muscle mass at 12 months after kidney transplantation (odds ratio [OR]: 0.34; 95% confidence interval [CI]: 0.16-0.72; P = 0.005). The pre-transplantation phase angle was not significantly associated with low HGS (OR: 0.37; 95% CI 0.12-1.17; P = 0.090) 12 months after kidney transplantation.

Conclusions: Pre-transplantation phase angle can predict muscle mass status 12 months after kidney transplantation.

背景:本研究旨在评估肾移植患者的相位角、肌肉力量和肌肉质量之间的关系:本研究旨在评估肾移植患者的相位角、肌肉力量和肌肉质量之间的关系:方法:研究对象为肾移植术前和术后测量相位角的患者。在移植前、移植后 7 天和 14 天以及移植后 3、6 和 12 个月时,使用多频生物阻抗分析装置测量相位角和身体成分。肌肉力量采用手握力量(HGS)进行评估。男性和女性的低 HGS 定义为 2:对 88 名患者(平均年龄为 52.3 ± 10.1 岁)进行了分析。移植前的平均相位角为 5.0 ± 1.0°。移植后 6 个月和 12 个月的体脂率明显高于移植前(P 结论:移植前的相位角对移植后的体脂率有影响:移植前相位角可预测肾移植 12 个月后的肌肉质量状况。
{"title":"The phase angle before transplantation can predict the status of low muscle mass after kidney transplantation.","authors":"Hyo Jin Kim, Eun Young Seong, Hyuk Jae Jung, Sang Heon Song","doi":"10.1007/s10157-024-02543-1","DOIUrl":"https://doi.org/10.1007/s10157-024-02543-1","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to evaluate the association between phase angle, muscle strength, and muscle mass in patients undergoing kidney transplantation.</p><p><strong>Methods: </strong>Patients whose pre- and follow-up phase angles were measured after kidney transplantation were enrolled. Phase angle and body composition were measured using a multi-frequency bioimpedance analysis device before and at 7 and 14 days and 3, 6, and 12 months after transplantation. Muscle strength was evaluated using handgrip strength (HGS). Low HGS was defined as < 28 kg in males and < 18 kg in females. Low muscle mass was defined as an appendicular lean mass index of < 7.0 kg/m<sup>2</sup> in males and < 5.7 kg/m<sup>2</sup> in females.</p><p><strong>Results: </strong>Eighty-eight patients (mean age 52.3 ± 10.1 years) were analyzed. The mean phase angle of pre-transplantation was 5.0 ± 1.0°. Body fat percentage was significantly higher at 6 and 12 months after transplantation than pre-transplantation (P < 0.0001). Twelve months after kidney transplantation, the prevalence of low HGS decreased (pre-transplantation vs. 12 months post-transplantation: 28.4% vs. 17.0%), and the prevalence of low muscle mass (pre-transplantation vs. 12 months post-transplantation: 21.6% vs. 28.4%) increased. The pre-transplantation phase angle was significantly associated with low muscle mass at 12 months after kidney transplantation (odds ratio [OR]: 0.34; 95% confidence interval [CI]: 0.16-0.72; P = 0.005). The pre-transplantation phase angle was not significantly associated with low HGS (OR: 0.37; 95% CI 0.12-1.17; P = 0.090) 12 months after kidney transplantation.</p><p><strong>Conclusions: </strong>Pre-transplantation phase angle can predict muscle mass status 12 months after kidney transplantation.</p>","PeriodicalId":10349,"journal":{"name":"Clinical and Experimental Nephrology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142016578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Straightforward and immediate ultrasound-guided kidney biopsy using a guide needle technique to get adequate tissue with reduced procedural time. 使用导针技术,在超声波引导下进行直接、即时的肾脏活组织检查,以获取足够的组织并缩短手术时间。
IF 2.2 4区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-08-22 DOI: 10.1007/s10157-024-02544-0
Hiroaki Komatsu, Tomohisa Yamashita, Arata Osanami, Chikako Akazawa, Kota Endo, Shun Tsugawa, Ayumu Kimura, Daisuke Miyamori, Koki Abe, Satoko Takahashi, Yufu Gocho, Masayuki Koyama, Tatsuya Sato, Marenao Tanaka, Norihito Moniwa, Masato Furuhashi

Background: A streamlined and effective renal biopsy technique is essential for all nephrologists, particularly those who are less experienced, such as residents. Herein, we report the efficacy of a Straightforward and Immediate ultrasound-guided kidney biopsy using a Guide Needle (SIGN) technique, which allows operators to insert a biopsy gun through a guide needle placed into the fascia of the posterior abdominal wall.

Methods: A retrospective cross-sectional study was conducted at a nephrology training institution to compare the time spent on the procedure and the number of glomeruli obtained between a group using the SIGN (n = 81) and a group using the conventional ultrasound-guided kidney biopsy technique with a needle guide device (n = 143).

Results: The median procedure time in the SIGN group (2 min, interquartile range [IQR]: 1-3 min) was significantly shorter than that in the conventional group (3 min, IQR: 2-4 min) (P < 0.001). Multivariable linear regression and logistic regression analyses adjusted for covariates, including operators (board-certificated nephrologists or nephrology residents), showed that the use of the SIGN technique was independently associated with a high number of glomeruli obtained and a procedure time above 2 min as the median value (odds ratio: 0.17, 95% confidence interval CI 0.09-0.34). The prevalence of complications was comparable between the two groups (P = 0.681).

Conclusion: The SIGN technique reduces the procedure time and obtains adequate biopsy tissue regardless of the operator's experience. SIGN can be applied in nephrology training programs and used as a standard biopsy technique.

背景:对于所有肾脏病医生,尤其是经验较少的住院医生来说,简化而有效的肾活检技术至关重要。在此,我们报告了使用导针的直接即时超声引导肾活检(SIGN)技术的有效性,该技术允许操作者通过放置在后腹壁筋膜中的导针插入活检枪:方法:在一家肾脏病培训机构进行了一项回顾性横断面研究,比较了使用SIGN技术组(81人)和使用带导针装置的传统超声引导肾脏活检技术组(143人)的手术时间和获得的肾小球数量:结果:SIGN组的中位手术时间(2分钟,四分位数间距[IQR]:1-3分钟)明显短于传统组(3分钟,四分位数间距[IQR]:2-4分钟):无论操作者的经验如何,SIGN 技术都能缩短手术时间并获得足够的活检组织。SIGN 可应用于肾脏内科培训项目,并作为标准活检技术使用。
{"title":"Straightforward and immediate ultrasound-guided kidney biopsy using a guide needle technique to get adequate tissue with reduced procedural time.","authors":"Hiroaki Komatsu, Tomohisa Yamashita, Arata Osanami, Chikako Akazawa, Kota Endo, Shun Tsugawa, Ayumu Kimura, Daisuke Miyamori, Koki Abe, Satoko Takahashi, Yufu Gocho, Masayuki Koyama, Tatsuya Sato, Marenao Tanaka, Norihito Moniwa, Masato Furuhashi","doi":"10.1007/s10157-024-02544-0","DOIUrl":"https://doi.org/10.1007/s10157-024-02544-0","url":null,"abstract":"<p><strong>Background: </strong>A streamlined and effective renal biopsy technique is essential for all nephrologists, particularly those who are less experienced, such as residents. Herein, we report the efficacy of a Straightforward and Immediate ultrasound-guided kidney biopsy using a Guide Needle (SIGN) technique, which allows operators to insert a biopsy gun through a guide needle placed into the fascia of the posterior abdominal wall.</p><p><strong>Methods: </strong>A retrospective cross-sectional study was conducted at a nephrology training institution to compare the time spent on the procedure and the number of glomeruli obtained between a group using the SIGN (n = 81) and a group using the conventional ultrasound-guided kidney biopsy technique with a needle guide device (n = 143).</p><p><strong>Results: </strong>The median procedure time in the SIGN group (2 min, interquartile range [IQR]: 1-3 min) was significantly shorter than that in the conventional group (3 min, IQR: 2-4 min) (P < 0.001). Multivariable linear regression and logistic regression analyses adjusted for covariates, including operators (board-certificated nephrologists or nephrology residents), showed that the use of the SIGN technique was independently associated with a high number of glomeruli obtained and a procedure time above 2 min as the median value (odds ratio: 0.17, 95% confidence interval CI 0.09-0.34). The prevalence of complications was comparable between the two groups (P = 0.681).</p><p><strong>Conclusion: </strong>The SIGN technique reduces the procedure time and obtains adequate biopsy tissue regardless of the operator's experience. SIGN can be applied in nephrology training programs and used as a standard biopsy technique.</p>","PeriodicalId":10349,"journal":{"name":"Clinical and Experimental Nephrology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142016577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exposure and outcomes of aortic valve change in patients initiating dialysis. 开始透析的患者主动脉瓣变化的风险和结果。
IF 2.2 4区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-08-22 DOI: 10.1007/s10157-024-02548-w
Mineaki Kitamura, Hiroshi Yamashita, Atsushi Sawase, Masayoshi Takeno, Koji Maemura, Hiroshi Mukae, Tomoya Nishino

Background: Aortic stenosis (AS) and aortic valve calcification (AVC) are occasionally observed in patients receiving maintenance dialysis. However, their prevalence and factors associated with them in patients undergoing dialysis remain unknown. We aimed to elucidate the aortic valve status at the time of dialysis initiation and patient prognosis based on aortic valve status.

Methods: We analyzed 289 patients initiating dialysis (hemodialysis: peritoneal dialysis = 275:14) between 2016 and 2023. "AS and/or AVC" was detected using echocardiography. AS was defined as a maximum transaortic velocity > 2.0 m/s. Statistical analyses including multivariable logistic regression and Cox regression were used to assess the association between patient characteristics and survival outcomes.

Results: Aortic valve changes were observed in 121 (42%) patients, among which 33 (11%) met the AS criteria. The mean age of patients in the AS, AVC without AS, and control groups was 79.1 ± 8.9, 75.9 ± 9.2, and 68.3 ± 12.9, respectively (P < 0.001). Multivariable logistic regression models showed that only age was associated with aortic valve changes (P < 0.001). Age and other important factor-adjusted multivariable Cox regression models showed that AS was an independent risk factor for death after dialysis initiation (hazard ratio (HR): 1.95, 95% confidence interval (CI): 1.06 - 3.59, P = 0.04). However, aortic valve changes ("AS and/or AVC") were not a risk factor for death (HR: 1.51, 95% CI 0.95 - 2.39, P = 0.08).

Conclusions: With the growing older population undergoing dialysis, aortic valve changes should be closely monitored. Particularly, AS is crucial because of its impact on patient prognosis.

背景:接受维持性透析的患者偶尔会出现主动脉瓣狭窄(AS)和主动脉瓣钙化(AVC)。然而,它们在透析患者中的发病率及其相关因素仍不清楚。我们的目的是阐明开始透析时的主动脉瓣状态以及基于主动脉瓣状态的患者预后:我们分析了2016年至2023年间开始透析的289名患者(血液透析:腹膜透析=275:14)。"AS和/或AVC "通过超声心动图检测。AS定义为最大经主动脉速度大于2.0 m/s。统计分析包括多变量逻辑回归和 Cox 回归,以评估患者特征与生存结果之间的关联:121例(42%)患者出现主动脉瓣病变,其中33例(11%)符合AS标准。AS组、AVC无AS组和对照组患者的平均年龄分别为(79.1±8.9)岁、(75.9±9.2)岁和(68.3±12.9)岁(P随着接受透析的老年人口不断增加,应密切监测主动脉瓣的变化。尤其是主动脉瓣狭窄,因为它影响患者的预后。
{"title":"Exposure and outcomes of aortic valve change in patients initiating dialysis.","authors":"Mineaki Kitamura, Hiroshi Yamashita, Atsushi Sawase, Masayoshi Takeno, Koji Maemura, Hiroshi Mukae, Tomoya Nishino","doi":"10.1007/s10157-024-02548-w","DOIUrl":"https://doi.org/10.1007/s10157-024-02548-w","url":null,"abstract":"<p><strong>Background: </strong>Aortic stenosis (AS) and aortic valve calcification (AVC) are occasionally observed in patients receiving maintenance dialysis. However, their prevalence and factors associated with them in patients undergoing dialysis remain unknown. We aimed to elucidate the aortic valve status at the time of dialysis initiation and patient prognosis based on aortic valve status.</p><p><strong>Methods: </strong>We analyzed 289 patients initiating dialysis (hemodialysis: peritoneal dialysis = 275:14) between 2016 and 2023. \"AS and/or AVC\" was detected using echocardiography. AS was defined as a maximum transaortic velocity > 2.0 m/s. Statistical analyses including multivariable logistic regression and Cox regression were used to assess the association between patient characteristics and survival outcomes.</p><p><strong>Results: </strong>Aortic valve changes were observed in 121 (42%) patients, among which 33 (11%) met the AS criteria. The mean age of patients in the AS, AVC without AS, and control groups was 79.1 ± 8.9, 75.9 ± 9.2, and 68.3 ± 12.9, respectively (P < 0.001). Multivariable logistic regression models showed that only age was associated with aortic valve changes (P < 0.001). Age and other important factor-adjusted multivariable Cox regression models showed that AS was an independent risk factor for death after dialysis initiation (hazard ratio (HR): 1.95, 95% confidence interval (CI): 1.06 - 3.59, P = 0.04). However, aortic valve changes (\"AS and/or AVC\") were not a risk factor for death (HR: 1.51, 95% CI 0.95 - 2.39, P = 0.08).</p><p><strong>Conclusions: </strong>With the growing older population undergoing dialysis, aortic valve changes should be closely monitored. Particularly, AS is crucial because of its impact on patient prognosis.</p>","PeriodicalId":10349,"journal":{"name":"Clinical and Experimental Nephrology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142016573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Children and adolescents with severe motor and intellectual disabilities who underwent kidney transplantation. 接受肾移植的严重运动和智力残疾儿童和青少年。
IF 2.2 4区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-08-22 DOI: 10.1007/s10157-024-02550-2
Ryo Nakatani, Kenichiro Miura, Taro Ando, Aya Kato, Yoko Shirai, Kiyonobu Ishizuka, Yuki Miyauchi, Daisuke Ogino, Yuko Akioka, Hideki Ishida, Motoshi Hattori

Background: Kidney transplantation (KT) in children and adolescents with severe motor and intellectual disabilities (SMID) has been a topic of controversy. A multicenter study in Japan showed that KT was not contraindicated for children with multiple handicaps, but no consensus has been reached on KT for patients with SMID. This study aimed to determine whether KT is a viable treatment option for children and adolescents with SMID.

Methods: A single-center, retrospective study was conducted on children and adolescents with SMID who underwent KT. SMID was defined based on Oshima's classification. Clinical information was collected through a review of medical records.

Results: Of 453 children and adolescents who underwent KT between 1983 and 2023 in our institution, six (1.3%) patients with SMID were identified. One patient received KT twice. All patients underwent living KT. Five patients used medical devices, including gastrostomy and a ventriculoperitoneal shunt, prior to KT. Perioperative complications, including hemothorax related to central venous catheter insertion, ventilator-associated pneumonia, and common iliac artery thrombosis requiring graftectomy, occurred in three patients. One patient required vesicostomy owing to refractory urinary tract infection. There was no significant difference in the graft survival rate between patients with SMID and those without SMID. One patient developed graft failure and died after selecting conservative kidney management.

Conclusion: Our study showed a favorable graft survival in children and adolescents with SMID who underwent KT. Although careful perioperative management and continued medical care are required, KT may be a viable option for these patients.

背景:严重运动和智力障碍(SMID)儿童和青少年的肾移植(KT)一直是一个有争议的话题。日本的一项多中心研究表明,KT 并非多重残疾儿童的禁忌症,但对于严重运动障碍和智力障碍(SMID)患者的 KT 还未达成共识。本研究旨在确定 KT 是否是 SMID 儿童和青少年的可行治疗方案:方法:对接受 KT 的 SMID 儿童和青少年进行了一项单中心回顾性研究。SMID的定义基于大岛的分类。通过查阅病历收集临床信息:结果:1983年至2023年间,我院共有453名儿童和青少年接受了KT治疗,其中发现了6名(1.3%)SMID患者。一名患者接受了两次 KT。所有患者均接受了活体 KT。五名患者在接受 KT 之前使用了医疗设备,包括胃造瘘术和脑室腹腔分流术。三位患者出现了围手术期并发症,包括与中心静脉导管插入有关的血胸、呼吸机相关性肺炎和髂总动脉血栓,需要进行颅骨切除术。一名患者因难治性尿路感染而需要进行膀胱造口术。在移植物存活率方面,有 SMID 的患者与没有 SMID 的患者没有明显差异。一名患者在选择保守肾脏治疗后出现移植失败并死亡:我们的研究表明,接受 KT 的 SMID 儿童和青少年的移植物存活率较高。尽管需要谨慎的围手术期管理和持续的医疗护理,但 KT 可能是这些患者的可行选择。
{"title":"Children and adolescents with severe motor and intellectual disabilities who underwent kidney transplantation.","authors":"Ryo Nakatani, Kenichiro Miura, Taro Ando, Aya Kato, Yoko Shirai, Kiyonobu Ishizuka, Yuki Miyauchi, Daisuke Ogino, Yuko Akioka, Hideki Ishida, Motoshi Hattori","doi":"10.1007/s10157-024-02550-2","DOIUrl":"https://doi.org/10.1007/s10157-024-02550-2","url":null,"abstract":"<p><strong>Background: </strong>Kidney transplantation (KT) in children and adolescents with severe motor and intellectual disabilities (SMID) has been a topic of controversy. A multicenter study in Japan showed that KT was not contraindicated for children with multiple handicaps, but no consensus has been reached on KT for patients with SMID. This study aimed to determine whether KT is a viable treatment option for children and adolescents with SMID.</p><p><strong>Methods: </strong>A single-center, retrospective study was conducted on children and adolescents with SMID who underwent KT. SMID was defined based on Oshima's classification. Clinical information was collected through a review of medical records.</p><p><strong>Results: </strong>Of 453 children and adolescents who underwent KT between 1983 and 2023 in our institution, six (1.3%) patients with SMID were identified. One patient received KT twice. All patients underwent living KT. Five patients used medical devices, including gastrostomy and a ventriculoperitoneal shunt, prior to KT. Perioperative complications, including hemothorax related to central venous catheter insertion, ventilator-associated pneumonia, and common iliac artery thrombosis requiring graftectomy, occurred in three patients. One patient required vesicostomy owing to refractory urinary tract infection. There was no significant difference in the graft survival rate between patients with SMID and those without SMID. One patient developed graft failure and died after selecting conservative kidney management.</p><p><strong>Conclusion: </strong>Our study showed a favorable graft survival in children and adolescents with SMID who underwent KT. Although careful perioperative management and continued medical care are required, KT may be a viable option for these patients.</p>","PeriodicalId":10349,"journal":{"name":"Clinical and Experimental Nephrology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142016572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical and Experimental Nephrology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1